DRI Capital

Profile

DRI Capital is a private equity firm based in Toronto, founded in 1992. The firm specializes in investments in the pharmaceutical and healthcare sectors, focusing on acquiring dependable, patent-protected cash flow streams derived from the sales of important drugs. The team is characterized by its expertise in pharmaceutical royalty monetization and is known for its creative and flexible investment structures. DRI Capital's dedication to addressing unmet medical needs differentiates them in the industry.

DRI Capital invests primarily in the healthcare sector, with a particular emphasis on royalty streams from medically necessary products with long-term patent protection. They target investments in North America, Europe, and other regions with a focus on pharmaceuticals. While the exact check sizes are not publicly detailed, their strategic focus implies substantial investments in their target markets. The firm has a diversified portfolio, including interests in notable drugs such as Synagis, Remicade, and Keytruda.

Their portfolio boasts a wide range of investments in leading pharmaceutical products. Notable investments include Synagis, Remicade, Myozyme, Enbrel, and Soliris, showcasing DRI Capital's strategic focus on products with high growth potential and significant medical impact. The firm's approach in acquiring royalty streams has allowed them to build an extensive and varied portfolio, which underscores their commitment to value creation in the healthcare industry.